AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
trabectedin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| ecteinascidin derivatives | 4633 | 114899-77-3 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A complex structure that includes isoquinolines joined by a cyclic ester; it is a DNA-binding agent and guanine N2 alkylator derived from the marine tunicate, Ecteinascidia turbinata. Trabectedin is used for the treatment of advanced soft-tissue SARCOMA, after failure of ANTHRACYCLINES or IFOSFAMIDE drug therapy.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 25 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 12 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.06 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 44 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK2,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,IGF1R,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPK9,MAPKAPK2,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ZAP70 | 53 | |||
| kinase-selectivity-class | ACVR2B,EIF2AK3,GRK2,MAP2K6 | 4 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 4, 2015 | PMDA | ||
| Oct. 23, 2015 | FDA | JANSSEN PRODS | |
| Sept. 17, 2007 | EMA | Pharma Mar S.A. |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neutropenia | 278.94 | 46.04 | 150 | 3601 | 224754 | 90399942 |
| Pancytopenia | 203.20 | 46.04 | 99 | 3652 | 120164 | 90504532 |
| Febrile neutropenia | 180.24 | 46.04 | 100 | 3651 | 158249 | 90466447 |
| Thrombocytopenia | 169.68 | 46.04 | 106 | 3645 | 208619 | 90416077 |
| Anaemia | 166.21 | 46.04 | 128 | 3623 | 352674 | 90272022 |
| Rhabdomyolysis | 136.43 | 46.04 | 58 | 3693 | 51198 | 90573498 |
| Blood creatine phosphokinase increased | 105.65 | 46.04 | 43 | 3708 | 33980 | 90590716 |
| Alanine aminotransferase increased | 95.64 | 46.04 | 60 | 3691 | 118278 | 90506418 |
| Aspartate aminotransferase increased | 82.66 | 46.04 | 52 | 3699 | 102885 | 90521811 |
| Leukopenia | 73.72 | 46.04 | 48 | 3703 | 100662 | 90524034 |
| Neutrophil count decreased | 69.91 | 46.04 | 41 | 3710 | 71491 | 90553205 |
| Transaminases increased | 66.76 | 46.04 | 32 | 3719 | 37160 | 90587536 |
| Acute myeloid leukaemia | 63.75 | 46.04 | 26 | 3725 | 20614 | 90604082 |
| Disease progression | 60.95 | 46.04 | 51 | 3700 | 156564 | 90468132 |
| Capillary leak syndrome | 58.27 | 46.04 | 15 | 3736 | 2752 | 90621944 |
| Platelet count decreased | 49.98 | 46.04 | 43 | 3708 | 136926 | 90487770 |
| Asthenia | 48.12 | 46.04 | 82 | 3669 | 533669 | 90091027 |
| Nausea | 47.91 | 46.04 | 126 | 3625 | 1110190 | 89514506 |
| Extravasation | 47.77 | 46.04 | 13 | 3738 | 2951 | 90621745 |
| Hepatotoxicity | 46.68 | 46.04 | 27 | 3724 | 45815 | 90578881 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Haematotoxicity | 130.93 | 41.65 | 38 | 1731 | 10947 | 42608619 |
| Rhabdomyolysis | 96.28 | 41.65 | 52 | 1717 | 77967 | 42541599 |
| Pancytopenia | 71.74 | 41.65 | 50 | 1719 | 117693 | 42501873 |
| Thrombocytopenia | 64.25 | 41.65 | 57 | 1712 | 190222 | 42429344 |
| Hepatotoxicity | 62.05 | 41.65 | 27 | 1742 | 25140 | 42594426 |
| Disease progression | 54.41 | 41.65 | 46 | 1723 | 143610 | 42475956 |
| Alanine aminotransferase increased | 52.49 | 41.65 | 37 | 1732 | 88369 | 42531197 |
| Neutropenia | 52.39 | 41.65 | 52 | 1717 | 199379 | 42420187 |
| Aspartate aminotransferase increased | 49.79 | 41.65 | 34 | 1735 | 77129 | 42542437 |
| Transaminases increased | 46.32 | 41.65 | 24 | 1745 | 32861 | 42586705 |
| Neutrophil count decreased | 43.42 | 41.65 | 29 | 1740 | 63386 | 42556180 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Neutropenia | 237.55 | 42.08 | 168 | 4805 | 374452 | 110209874 |
| Pancytopenia | 224.68 | 42.08 | 131 | 4842 | 209482 | 110374844 |
| Thrombocytopenia | 183.68 | 42.08 | 140 | 4833 | 348745 | 110235581 |
| Rhabdomyolysis | 183.39 | 42.08 | 95 | 4878 | 120306 | 110464020 |
| Anaemia | 162.26 | 42.08 | 158 | 4815 | 546928 | 110037398 |
| Febrile neutropenia | 159.79 | 42.08 | 124 | 4849 | 316643 | 110267683 |
| Haematotoxicity | 153.45 | 42.08 | 51 | 4922 | 21031 | 110563295 |
| Disease progression | 121.73 | 42.08 | 95 | 4878 | 243939 | 110340387 |
| Alanine aminotransferase increased | 114.99 | 42.08 | 82 | 4891 | 183691 | 110400635 |
| Aspartate aminotransferase increased | 101.48 | 42.08 | 72 | 4901 | 159864 | 110424462 |
| Neutrophil count decreased | 99.57 | 42.08 | 64 | 4909 | 120877 | 110463449 |
| Transaminases increased | 99.19 | 42.08 | 51 | 4922 | 63339 | 110520987 |
| Leukopenia | 92.12 | 42.08 | 66 | 4907 | 148725 | 110435601 |
| Hepatotoxicity | 84.96 | 42.08 | 46 | 4927 | 63354 | 110520972 |
| Blood creatine phosphokinase increased | 73.61 | 42.08 | 44 | 4929 | 73033 | 110511293 |
| Platelet count decreased | 70.63 | 42.08 | 68 | 4905 | 230375 | 110353951 |
| Hepatic function abnormal | 63.12 | 42.08 | 43 | 4930 | 89252 | 110495074 |
| Capillary leak syndrome | 57.10 | 42.08 | 17 | 4956 | 4891 | 110579435 |
| Acute myeloid leukaemia | 54.82 | 42.08 | 29 | 4944 | 38081 | 110546245 |
| Hypertransaminasaemia | 54.45 | 42.08 | 25 | 4948 | 24230 | 110560096 |
| Extravasation | 48.72 | 42.08 | 15 | 4958 | 4830 | 110579496 |
| White blood cell count decreased | 45.90 | 42.08 | 54 | 4919 | 229336 | 110354990 |
| Device related infection | 42.93 | 42.08 | 25 | 4948 | 39494 | 110544832 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01CX01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS Other plant alkaloids and natural products |
| FDA MoA | N0000000236 | Alkylating Activity |
| FDA EPC | N0000175558 | Alkylating Drug |
| MeSH PA | D000477 | Alkylating Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D018906 | Antineoplastic Agents, Alkylating |
| CHEBI has role | CHEBI:22333 | alkylating agent |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:50926 | angiogenesis modulating agent |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| CHEBI has role | CHEBI:76507 | marine metabolite |
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Liposarcoma | indication | 254829001 | DOID:3382 |
| Malignant tumor of ovary | indication | 363443007 | DOID:2394 |
| Leiomyosarcoma | indication | 443719001 | DOID:1967 |
| Soft or Connective Tissue Sarcoma | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 9.18 | acidic |
| pKa2 | 10.36 | acidic |
| pKa3 | 10.93 | acidic |
| pKa4 | 8.21 | Basic |
| pKa5 | 7.59 | Basic |
| pKa6 | 1.0 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Proto-oncogene tyrosine-protein kinase Src | Kinase | IC50 | 6.68 | CHEMBL | |||||
| Nuclear receptor subfamily 1 group I member 2 | Nuclear hormone receptor | ANTAGONIST | IC50 | 8.52 | IUPHAR |
External reference:
| ID | Source |
|---|---|
| D06199 | KEGG_DRUG |
| 4035010 | VANDF |
| CHEBI:84050 | CHEBI |
| ECT | PDB_CHEM_ID |
| CHEMBL450449 | ChEMBL_ID |
| 2774 | IUPHAR_LIGAND_ID |
| 8206 | INN_ID |
| DB05109 | DRUGBANK_ID |
| ID0YZQ2TCP | UNII |
| 1716278 | RXNORM |
| 165758 | MMSL |
| 26244 | MMSL |
| d07398 | MMSL |
| 012537 | NDDF |
| 432214004 | SNOMEDCT_US |
| 433127001 | SNOMEDCT_US |
| C1311070 | UMLSCUI |
| D000077606 | MESH_DESCRIPTOR_UI |
| 108150 | PUBCHEM_CID |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| YONDELIS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59676-610 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.05 mg | INTRAVENOUS | NDA | 30 sections |
| YONDELIS | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59676-610 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 0.05 mg | INTRAVENOUS | NDA | 30 sections |
| EVDI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6423 | INJECTION, SOLUTION, CONCENTRATE | 0.05 mg | INTRAVENOUS | NDA | 29 sections |